$106.61 Million in Sales Expected for Genomic Health, Inc. (GHDX) This Quarter

Wall Street brokerages expect that Genomic Health, Inc. (NASDAQ:GHDX) will post sales of $106.61 million for the current quarter, according to Zacks Investment Research. Seven analysts have provided estimates for Genomic Health’s earnings, with the highest sales estimate coming in at $108.10 million and the lowest estimate coming in at $104.87 million. Genomic Health reported sales of $92.63 million during the same quarter last year, which indicates a positive year over year growth rate of 15.1%. The business is expected to issue its next quarterly earnings results on Wednesday, May 1st.

According to Zacks, analysts expect that Genomic Health will report full year sales of $444.60 million for the current year, with estimates ranging from $438.47 million to $450.85 million. For the next fiscal year, analysts anticipate that the business will report sales of $491.97 million, with estimates ranging from $480.72 million to $503.40 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that cover Genomic Health.

Genomic Health (NASDAQ:GHDX) last released its quarterly earnings data on Wednesday, February 20th. The medical research company reported $0.32 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.30 by $0.02. Genomic Health had a net margin of 6.52% and a return on equity of 16.86%. The firm had revenue of $104.56 million for the quarter, compared to the consensus estimate of $101.55 million. During the same quarter in the prior year, the company posted $0.05 earnings per share. The business’s revenue was up 22.0% on a year-over-year basis.

A number of equities research analysts recently weighed in on the stock. BidaskClub lowered shares of Genomic Health from a “buy” rating to a “hold” rating in a report on Saturday, March 30th. ValuEngine downgraded Genomic Health from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, March 5th. Piper Jaffray Companies boosted their price objective on Genomic Health to $86.00 and gave the stock a “neutral” rating in a report on Thursday, February 21st. Needham & Company LLC reissued a “strong-buy” rating and issued a $97.00 price objective (up from $86.00) on shares of Genomic Health in a research note on Thursday, February 21st. Finally, CIBC started coverage on Genomic Health in a report on Wednesday, December 19th. They issued a “market perform” rating on the stock. Ten investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $63.13.

In other news, Director Bros. Advisors Lp Baker sold 600 shares of the firm’s stock in a transaction on Thursday, February 28th. The stock was sold at an average price of $76.20, for a total transaction of $45,720.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Steven Shak sold 75,000 shares of the firm’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $68.56, for a total value of $5,142,000.00. The disclosure for this sale can be found here. Insiders sold a total of 2,268,338 shares of company stock valued at $165,109,141 over the last ninety days. 45.80% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. raised its position in Genomic Health by 7.6% in the fourth quarter. BlackRock Inc. now owns 2,191,689 shares of the medical research company’s stock worth $141,167,000 after acquiring an additional 154,253 shares during the period. Vanguard Group Inc increased its stake in shares of Genomic Health by 18.6% during the 3rd quarter. Vanguard Group Inc now owns 2,151,932 shares of the medical research company’s stock worth $151,109,000 after purchasing an additional 337,664 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Genomic Health by 18.6% during the 3rd quarter. Vanguard Group Inc. now owns 2,151,932 shares of the medical research company’s stock worth $151,109,000 after purchasing an additional 337,664 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of Genomic Health by 26.9% during the 3rd quarter. Renaissance Technologies LLC now owns 1,783,100 shares of the medical research company’s stock worth $125,209,000 after purchasing an additional 378,176 shares during the last quarter. Finally, Acadian Asset Management LLC raised its holdings in shares of Genomic Health by 41.1% in the 4th quarter. Acadian Asset Management LLC now owns 741,268 shares of the medical research company’s stock worth $47,741,000 after purchasing an additional 215,892 shares during the period. Institutional investors own 90.48% of the company’s stock.

Shares of NASDAQ:GHDX traded up $2.00 during midday trading on Monday, hitting $68.60. 580,953 shares of the company’s stock were exchanged, compared to its average volume of 655,424. The company has a market cap of $2.46 billion, a PE ratio of 65.33 and a beta of 0.95. Genomic Health has a 12 month low of $30.76 and a 12 month high of $92.18.

Genomic Health Company Profile

Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.

See Also: How to Trade Using Analysts Ratings

Get a free copy of the Zacks research report on Genomic Health (GHDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.